Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.

Mansoor R MirzaAntonio González-MartínWhitney S GraybillDavid M O'MalleyLydia GabaOi Wah Stephanie YapEva M GuerraPeter G RoseJean-François BaurainSharad A GhamandeHannelore DenysEmily PrendergastCarmela PisanoPhilippe FollanaKlaus BaumannPaula M CalvertJacob KorachYong LiIzabela A MalinowskaDivya GuptaBradley J Monk

Published in: Cancer (2023)

In PRIMA, similar dose intensity, similar efficacy, and improved safety were observed with the ISD compared with the FSD regimen.

Keyphrases

body weight
open label
clinical trial
study protocol
phase iii
peripheral blood
phase ii
high intensity
randomized controlled trial